Please wait a minute...
Reviews in Cardiovascular Medicine  2020, Vol. 21 Issue (4): 615-625     DOI: 10.31083/j.rcm.2020.04.113
Original Research Previous articles | Next articles
Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study
Qi Yao1, 2, 3, , Jian Ni 1, 2, 3, , Tong-Tong Hu1, 2, 3, Zhu-Lan Cai1, 2, 3, Jin-Hua Zhao1, 2, 3, Qing-Wen Xie1, 2, 3, Chen Liu1, 2, 3, Qing-Qing Wu1, 2, 3, *()
1Department of Cardiology, Renmin Hospital of Wuhan University, 430060, Wuhan, P. R. China
2Cardiovascular Research Institute, Wuhan University, 430060, Wuhan, P. R. China
3Hubei Key Laboratory of Cardiology, 430060, Wuhan, P. R. China
Download:  PDF(536KB)  ( 200 ) Full text   ( 21 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
The novel coronavirus disease (COVID-19) has spread all over the world in a short time. Information about the differences between COVID-19 patients with and without hypertension is limited. To explore the characteristics and outcomes differences between COVID-19 patients with and without hypertension, the medical records and cardiac biomarkers of 414 patients were analyzed. A total of 149 patients had a history of hypertension, while 265 patients did not have hypertension, and the groups were compared based on their clinical characteristics and laboratory findings as well as the hazard risk for composite outcomes, including intensive care unit (ICU) admission, mechanical ventilation, or death. The results are as follows. On admission, 22.1% of patients in hypertension group had elevated high sensitivity troponin I (hs-TNI > 26 pg/mL), which was higher than the proportion in the nonhypertension group (6.4%). Median NT-proBNP levels in patients with hypertension (141.9 pg/mL) were higher than those in patients without hypertension (77.3 pg/mL). Patients in the hypertension group had a higher risk for in-hospital death [HR: 2.57, 95% CI (1.46~4.51)]. However, the impact of hypertension on the prognosis was not significant after adjusting for age and sex. Multivariate Cox hazard regression confirmed that NT-proBNP levels in the highest tertile (upper 75 % of patients with hypertension) was an independent risk factor for in-hospital death in all COVID-19 patients. Taken together, hypertension per se had a modest impact on the prognosis in COVID-19 patients. In COVID-19 patients with and without hypertension, NT-proBNP may be a better predictor of prognosis than hs-TNI.
Key words:  COVID-19      hypertension      clinical outcomes      hs-TNI      NT-proBNP     
Submitted:  06 June 2020      Revised:  25 October 2020      Accepted:  26 October 2020      Published:  30 December 2020     
*Corresponding Author(s):  Qing-Qing Wu     E-mail:  qingwu20130@whu.edu.cn
About author:  These authors contributed equally.

Cite this article: 

Qi Yao, Jian Ni , Tong-Tong Hu, Zhu-Lan Cai, Jin-Hua Zhao, Qing-Wen Xie, Chen Liu, Qing-Qing Wu. Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Reviews in Cardiovascular Medicine, 2020, 21(4): 615-625.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm.2020.04.113     OR     https://rcm.imrpress.com/EN/Y2020/V21/I4/615

[1] Ritu Thamman, Rajesh Janardhanan. Cardiac rehabilitation using telemedicine: the need for tele cardiac rehabilitation[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 497-500.
[2] Alexandru Burlacu, Radu Crisan-Dabija, Adrian Covic, Catalin Raiu, Ionut Mavrichi, Iolanda Valentina Popa, Manuel Lillo-Crespo. Pandemic lockdown, healthcare policies and human rights: integrating opposed views on COVID-19 public health mitigation measures[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 509-516.
[3] Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett, Robert L. Berkowitz, Andrew C. Berry, Thomas J. Borody, Joseph H. Brewer, Adam M. Brufsky, Teryn Clarke, Roland Derwand, Alieta Eck, John Eck, Richard A. Eisner, George C. Fareed, Angelina Farella, Silvia N. S. Fonseca, Charles E. Geyer Jr., Russell S. Gonnering, Karladine E. Graves, Kenneth B. V. Gross, Sabine Hazan, Kristin S. Held, H. Thomas Hight, Stella Immanuel, Michael M. Jacobs, Joseph A. Ladapo, Lionel H. Lee, John Littell, Ivette Lozano, Harpal S. Mangat, Ben Marble, John E. McKinnon, Lee D. Merritt, Jane M. Orient, Ramin Oskoui, Donald C. Pompan, Brian C. Procter, Chad Prodromos, Juliana Cepelowicz Rajter, Jean-Jacques Rajter, C. Venkata S. Ram, Salete S. Rios , Harvey A. Risch, Michael J. A. Robb, Molly Rutherford, Martin Scholz, Marilyn M. Singleton, James A. Tumlin, Brian M. Tyson, Richard G. Urso, Kelly Victory, Elizabeth Lee Vliet, Craig M. Wax, Alexandre G. Wolkoff, Vicki Wooll, Vladimir Zelenko. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 517-530.
[4] Jasjit S. Suri, Anudeep Puvvula, Misha Majhail, Mainak Biswas, Ankush D. Jamthikar, Luca Saba, Gavino Faa, Inder M. Singh, Ronald Oberleitner, Monika Turk, Saurabh Srivastava, Paramjit S. Chadha, Harman S. Suri, Amer M. Johri, Vijay Nambi, J Miguel Sanches , Narendra N. Khanna, Klaudija Viskovic, Sophie Mavrogeni, John R. Laird, Arindam Bit, Gyan Pareek, Martin Miner, Antonella Balestrieri, Petros P. Sfikakis, George Tsoulfas, Athanasios Protogerou, Durga Prasanna Misra, Vikas Agarwal, George D. Kitas, Raghu Kolluri, Jagjit Teji, Michele Porcu, Mustafa Al-Maini, Ann Agbakoba, Meyypan Sockalingam, Ajit Sexena, Andrew Nicolaides, Aditya Sharma, Vijay Rathore, Vijay Viswanathan, Subbaram Naidu, Deepak L. Bhatt. Integration of cardiovascular risk assessment with COVID-19 using artificial intelligence[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 541-560.
[5] A. Verner Venegas-Vera, Gates B Colbert, Edgar V. Lerma. Positive and negative impact of social media in the COVID-19 era[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 561-564.
[6] Chia-Te Liao, Wei-Ting Chang, Wen-Liang Yu, Han Siong Toh. Management of acute cardiovascular events in patients with COVID-19[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 577-581.
[7] Gates B. Colbert, A. Verner Venegas-Vera, Edgar V. Lerma. Utility of telemedicine in the COVID-19 era[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 583-587.
[8] Brian C. Procter, Casey Ross, Vanessa Pickard, Erica Smith, Cortney Hanson, Peter A. McCullough. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 611-614.
[9] Kihyun Kim, Jong-Youn Kim, Eui-Young Choi, Hyuck-Moon Kwon, Se-Joong Rim. Prevalence and risk factors for secondary hypertension among young Korean men[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 627-634.
[10] Niloofar Deravi, Mobina Fathi, Kimia Vakili, Shirin Yaghoobpoor, Marzieh Pirzadeh, Melika Mokhtari, Tara Fazel, Elahe Ahsan, Samad Ghaffari. SARS-CoV-2 infection in patients with diabetes mellitus and hypertension: a systematic review[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 385-397.
[11] Ramesh K. Goyal, Jaseela Majeed, Rajiv Tonk, Mahaveer Dhobi, Bhoomika Patel, Kalicharan Sharma, Subbu Apparsundaram. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 365-384.
[12] Jun Zhang, Kristen M. Tecson, Peter A. McCullough. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 315-319.
[13] Jun Zhang, Peter A. McCullough, Kristen M. Tecson. Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 339-344.
[14] Allison Zimmerman, Dinesh Kalra. Usefulness of machine learning in COVID-19 for the detection and prognosis of cardiovascular complications[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 345-352.
[15] Ajay K. Mahenthiran, Ashorne K. Mahenthiran, Jo Mahenthiran. Cardiovascular system and COVID-19: manifestations and therapeutics[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 399-409.
No Suggested Reading articles found!